{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:09:41Z","timestamp":1784668181126,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research FundingInterdepartmental Clinical Research Project of Peking University First Hospital","award":["2024IR06"],"award-info":[{"award-number":["2024IR06"]}]},{"name":"Peking University Clinical Scientist Training Program","award":["BMU2025PYJH006"],"award-info":[{"award-number":["BMU2025PYJH006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Retroperitoneal lymph node metastasis (rLNM) of upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) represents a distinct metastatic state. Due to the unclear efficacy and side effects of radiotherapy in the treatment of these patients.This study aimed to assess the efficacy and adverse effects of radiotherapy combined with systemic therapy in rLNM patients after RNU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 114 UTUC patients with retroperitoneal LNM after RNU were prospectively enrolled database with retroperitoneal LNM after RNU. Patients were classified by initial treatment type: (1) radiation therapy, (2) systemic therapy or (3) combination therapy. Cox proportional hazard models were used to assess the factors associated with progression free survival (PFS) and overall survival (OS). Survival curves for each group were generated and compared via the Kaplan\u2012Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 114 rLNM patients with a median recurrence-free interval of 8\u00a0months after surgery (range: 1\u2013108) were analyzed. During the median follow-up of 22\u00a0months (range: 3\u201381\u00a0months), 60 patients (58.8%) developed distant metastases. The para-aortic region was the most frequent site of recurrence. The recurrence rate in this region was significantly higher in patients with renal pelvic and proximal ureteral tumors (UTUCs) than in those with middle and distal UTUCs (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.046). The common iliac region was the second most common recurrence site. Compared with renal pelvic tumors, ureteral tumors were more likely to recur in the common iliac region (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). We delineated the radiotherapy clinical target volume (CTV) on the basis of primary tumor site; only 3 patients developed in-field recurrence during follow-up.The 2-year PFS rates for the combination therapy, radiation therapy and systemic therapy groups were 65.7%, 21.1% and 20.2%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The 2-year OS rates for the combination therapy, radiation therapy and systemic therapy groups were 87.9%, 48.1% and 45.6%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Multivariate analysis revealed that combination therapy,radiotherapy beginning within 3\u00a0months after recurrence and maintenance therapy after radiation were independent predictors of PFS. Maintenance therapy after radiation and distant metastasis were significant predictors of OS. Among 55 patients, 1 patient (1.8%) experienced acute grade 3 adverse events during combination therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Systemic therapy and radiotherapy improved PFS compared with either therapy type alone in rLNM UTUC patients.The majority of patients experiencing only grade 1\u20132 gastrointestinal reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-03943-7","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:47:20Z","timestamp":1762872440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of radiotherapy combined with systemic therapy for retroperitoneal lymph node metastasis in upper tract urothelial carcinoma(UTUC) patients after radical nephroureterectomy"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaoying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Shu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunru","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"4","key":"3943_CR1","first-page":"212","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212\u201336.","journal-title":"CA Cancer J Clin"},{"issue":"10232","key":"3943_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2020;395(10232):1268\u201377.","journal-title":"Lancet (London, England)"},{"key":"3943_CR3","doi-asserted-by":"publisher","first-page":"529186","DOI":"10.1155\/2014\/529186","volume":"2014","author":"D Fang","year":"2014","unstructured":"Fang D, Zhang Q, Li X, Qian C, Xiong G, Zhang L, Chen X, Zhang X, Yu W, He Z, et al. Nomogram predicting renal insufficiency after nephroureterectomy for upper tract urothelial carcinoma in the Chinese population: exclusion of ineligible candidates for adjuvant chemotherapy. Biomed Res Int. 2014;2014:529186.","journal-title":"Biomed Res Int"},{"issue":"1","key":"3943_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, Seisen T, Birtle AJ, Capoun O, Comp\u00e9rat EM, Dominguez-Escrig JL, G\u00fcrses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023;84(1):49\u201364.","journal-title":"Eur Urol"},{"issue":"10","key":"3943_CR5","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.21037\/tau-21-47","volume":"10","author":"KM Gust","year":"2021","unstructured":"Gust KM, Resch I, D\u2019Andrea D, Shariat SF. Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. Transl Androl Urol. 2021;10(10):4051\u201361.","journal-title":"Transl Androl Urol"},{"issue":"1","key":"3943_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12957-020-01877-w","volume":"18","author":"X Li","year":"2020","unstructured":"Li X, Cui M, Gu X, Fang D, Li H, Qin S, Yang K, Zhu T, Li X, Zhou L, et al. Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma. World J Surg Oncol. 2020;18(1):114.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"3943_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/iju.15437","volume":"31","author":"K Uemura","year":"2024","unstructured":"Uemura K, Ito H, Jikuya R, Kondo T, Tatenuma T, Kawahara T, Ito Y, Komeya M, Muraoka K, Hasumi H, et al. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. International journal of urology\u202f: official journal of the Japanese Urological Association. 2024;31(6):678\u201384.","journal-title":"International journal of urology : official journal of the Japanese Urological Association"},{"issue":"7","key":"3943_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072069","volume":"15","author":"A Bertucci","year":"2023","unstructured":"Bertucci A, Cartier L, Rollet A, Boustany R, Hilgers W. Retrospective analysis of a cohort of patients with metastatic bladder cancer with metastatic sites limited to the pelvis and retroperitoneum treated at a single institution between 2009 and 2020. Cancers (Basel). 2023;15(7): 2069.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3943_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Comp\u00e9rat E, Dimitropoulos K, Efstathiou JA, Fietkau R, Kailavasan M, Lorch A, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol. 2025;87(5):582\u2013600.","journal-title":"Eur Urol"},{"issue":"3","key":"3943_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211\u20134.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3943_CR11","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J Clin Oncol. 2024;42(12):1391\u2013402.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3943_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.radonc.2008.11.007","volume":"92","author":"B Lengele","year":"2009","unstructured":"Lengele B, Scalliet P. Anatomical bases for the radiological delineation of lymph node areas. Part III: pelvis and lower limbs. Radiother Oncol. 2009;92(1):22\u201333.","journal-title":"Radiother Oncol"},{"key":"3943_CR13","first-page":"1","volume":"21","author":"Z Kang","year":"2025","unstructured":"Kang Z, Wang C, Xu W, Zhang B, Wan J, Li H, Shang P. Development and validation of a predictive model for postoperative metastasis of upper tract urothelial carcinoma after radical nephroureterectomy and analysis of risk factors for different metastatic sites: a multicenter study. Int Urol Nephrol. 2025;21:1\u20135.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"3943_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clgc.2015.10.006","volume":"14","author":"S Salah","year":"2016","unstructured":"Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, et al. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. Clin Genitourin Cancer. 2016;14(3):255\u201360.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"3943_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11934-016-0595-1","volume":"17","author":"JD Raman","year":"2016","unstructured":"Raman JD, Jafri SM. Complications following radical nephroureterectomy. Curr Urol Rep. 2016;17(5):36.","journal-title":"Curr Urol Rep"},{"issue":"1","key":"3943_CR16","doi-asserted-by":"publisher","first-page":"75.e71","DOI":"10.1016\/j.urolonc.2020.06.010","volume":"39","author":"X Li","year":"2021","unstructured":"Li X, Li S, Chi Z, Cui C, Si L, Yan X, Mao L, Lian B, Tang B, Wang X, et al. Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urol Oncol. 2021;39(1):75.e71-75.e78.","journal-title":"Urol Oncol"},{"issue":"7","key":"3943_CR17","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.21037\/tau-21-291","volume":"10","author":"MZ Liu","year":"2021","unstructured":"Liu MZ, Gao XS, Qin SB, Li XY, Ma MW, Xie M, Lyu F, Wang D. Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma. Transl Androl Urol. 2021;10(7):2929\u201337.","journal-title":"Transl Androl Urol"},{"issue":"6","key":"3943_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102216","volume":"22","author":"MZ Liu","year":"2024","unstructured":"Liu MZ, Li XY, Gao XS, Lyu F, Ma MW, Chen JY, Gao Y, Ren XY, Li XS. Outcomes of radical radiotherapy for the treatment of localized renal pelvic and ureteral carcinoma intolerant to surgery: a real-world study. Clin Genitourin Cancer. 2024;22(6): 102216.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"3943_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00345-023-04701-8","volume":"42","author":"MZ Liu","year":"2024","unstructured":"Liu MZ, Li XY, Lyu F, Gao XS, Chen JY, Gao Y, Xie M, Ren XY, Ma MW. Safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma. World J Urol. 2024;42(1):23.","journal-title":"World J Urol"},{"issue":"11","key":"3943_CR20","doi-asserted-by":"publisher","first-page":"790.e791","DOI":"10.1016\/j.urolonc.2021.05.005","volume":"39","author":"AF Miranda","year":"2021","unstructured":"Miranda AF, Howard JM, McLaughlin M, Meng X, Clinton T, \u015eanli \u00d6, Garant A, Bagrodia A, Margulis V, Lotan Y, et al. Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. Urol Oncol. 2021;39(11):790.e791-790.e797.","journal-title":"Urol Oncol"},{"issue":"6","key":"3943_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102203","volume":"22","author":"MZ Liu","year":"2024","unstructured":"Liu MZ, Chen JY, Lyu F, Gao XS, Ma MW, Li XY, Li HZ, Qin SB, Gao Y, Wang PY. Exploring radiotherapy as a promising alternative for managing advanced upper tract urothelial carcinoma: rescuing chemotherapy-intolerant patients. Clin Genitourin Cancer. 2024;22(6): 102203.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"3943_CR22","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.21873\/anticanres.16373","volume":"43","author":"T Sano","year":"2023","unstructured":"Sano T, Aizawa R, Ito K, Nakamura K, Ogata T, Takeda M, Hamada A, Matsuoka T, Kono J, Kita Y, et al. Efficacy and tolerability of second-line Pembrolizumab with radiation therapy in advanced urothelial carcinoma. Anticancer Res. 2023;43(5):2119\u201326.","journal-title":"Anticancer Res"},{"issue":"8","key":"3943_CR23","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/cancers15082278","volume":"15","author":"K Debbi","year":"2023","unstructured":"Debbi K, Grellier N, Loganadane G, Boukhobza C, Mah\u00e9 M, Cherif MA, Rida H, Gligorov J, Belkacemi Y. Interaction between radiation therapy and targeted therapies in HER2-positive breast cancer: literature review, levels of evidence for safety and recommendations for optimal treatment sequence. Cancers (Basel). 2023;15(8):2278.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3943_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ijrobp.2019.03.027","volume":"104","author":"M Kim","year":"2019","unstructured":"Kim M, Kim JK, Lee J, Kim YS, Lee JL, Kwak C, Jeong CW, Byun S-S, Lee SC, Ohyama C, et al. Adjuvant treatments for advanced stage, non-metastatic upper tract urothelial carcinoma: a multicenter study. Int J Radiat Oncol Biol Phys. 2019;104(4):819\u201327.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3943_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1471-2407-11-297","volume":"11","author":"B Chen","year":"2011","unstructured":"Chen B, Zeng ZC, Wang GM, Zhang L, Lin ZM, Sun LA, Zhu TY, Wu LL, Zhang JY, Ji Y. Radiotherapy may improve overall survival of patients with T3\/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. BMC Cancer. 2011;11:297.","journal-title":"BMC Cancer"},{"issue":"5","key":"3943_CR26","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1016\/j.prro.2021.02.005","volume":"11","author":"RW Gao","year":"2021","unstructured":"Gao RW, Tollefson MK, Thompson RH, Potretzke AM, Quevedo FJ, Choo R, Davis BJ, Pisansky TM, Harmsen WS, Stish BJ. Predictors of locoregional recurrence and delineation of adjuvant radiation therapy fields for patients with upper tract urothelial carcinoma receiving nephroureterectomy. Pract Radiat Oncol. 2021;11(5):e468-76.","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"3943_CR27","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.juro.2015.06.077","volume":"194","author":"SF Matin","year":"2015","unstructured":"Matin SF, Sfakianos JP, Espiritu PN, Coleman JA, Spiess PE. Patterns of lymphatic metastases in upper tract urothelial carcinoma and proposed dissection templates. J Urol. 2015;194(6):1567\u201374.","journal-title":"J Urol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03943-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:47:21Z","timestamp":1762872441000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03943-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3943"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03943-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and implementation of this study were approved by the Biomedical Ethics Committee of the First Hospital of Peking University(2019\u2013319 and 2022\u2013059). Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"428"}}